Clinical Trials ProgressPhase 3 NASH timelines remain on track, and Phase 3 SHTG data are expected, indicating progress in their clinical trials.
Regulatory StrategyPlans for accelerated and conditional approval in the U.S. and Europe for pegozafermin based on positive data from the ENLIGHTEN trials indicate potential future success.
Treatment EfficacyETNB is well-positioned with pegozafermin as a potentially best-in-class compound due to its competitive efficacy profile and differentiation on safety, tolerability, and dosing frequency.